Live
Funding 2 min read

Lithuanian startup secures $18 million Series A to scale AI-designed enzymes for industrial applications

Vilnius-based biotechnology company Biomatter has raised $18 million in an oversubscribed Series A funding round to expand its AI-driven enzyme design capabilities. The funds will be invested in establishing a new enzyme design and testing facility in Lithuania.

Image: ArcticStartup

Biomatter has successfully raised $18 million in an oversubscribed Series A funding round led by Astanor, according to ArcticStartup. The funding was also supported by existing investors UVC Partners, Inventure, and Metaplanet. This capital infusion will help Biomatter establish a dedicated facility for enzyme design and testing in Vilnius, Lithuania, enhancing their operational capabilities.

The new facility, spanning 2,000 square meters, is aimed at streamlining the development cycle for custom enzymes. Biomatter employs artificial intelligence to design enzymes targeted for applications in areas such as biopharmaceuticals and agricultural biotechnology. This funding will enable them to expedite the design process and meet the increasing demand for custom enzyme solutions.

The planned enzyme design and testing facility is expected to significantly reduce the time from design to testing, allowing Biomatter to better serve their growing customer base.

Reporting sources

Where this story comes from

1 reference

The facts above are grounded in the original reporting linked here. Open the publisher story for its complete context.

ArcticStartup Open source

Lithuanian startup secures $18 million Series A to scale AI-designed enzymes for industrial applications

The available publisher preview does not add detail beyond this brief. Open the original report for its full context.

Related coverage

Story history

No reviewed connections found in the current history window.

About this history review

The link graph’s cryptographic signature was verified. This proves integrity, not the truth of every claim or complete archive coverage.

Graph updated . Only articles retained in the public archive are included.

Open technical link data
Method & transparencyHow this brief was selected and checked
Editorial priority7 / 10

Priority

Source coverageSingle-source report

Single-source report

ConfidenceLimited

43 / 100 · one source

Source basis

Grounded in the publisher material listed below.

Confirmation

No second independent source has been matched to this story yet.

Selection

Selected for publication after relevance, freshness and editorial-quality checks.

Selection factors

  • 1 independent source
  • 1 concrete event indicator
  • editorial priority

Source monitoring: 89% recent availability · No source-health warnings. The original publisher remains the authoritative source for the full report.